Author Correction: Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
Sci Rep
.
2022 Sep 26;12(1):16052.
doi: 10.1038/s41598-022-20899-w.
Authors
Manaf AlQahtani
1
2
3
,
Nitya Kumar
4
,
Dhuha Aljawder
5
,
Abdulkarim Abdulrahman
6
7
,
Mohammed Wael Mohamed
8
,
Fatema Alnashaba
5
,
Mohammed Abu Fayyad
4
,
Faisal Alshaikh
9
,
Fatima Alsahaf
5
,
Sawsan Saeed
4
,
Amal Almahroos
5
,
Zainab Abdulrahim
5
,
Sameer Otoom
4
,
Stephen L Atkin
4
Affiliations
1
National Task Force for Combating the Corona Virus (COVID-19), Riffa, Bahrain. mqahtani@rcsi-mub.com.
2
Bahrain Defence Force Hospital, Riffa, Bahrain. mqahtani@rcsi-mub.com.
3
Royal College of Surgeons in Ireland, Riffa, Bahrain. mqahtani@rcsi-mub.com.
4
Royal College of Surgeons in Ireland, Riffa, Bahrain.
5
Salmaniya Medical Complex, Manama, Bahrain.
6
National Task Force for Combating the Corona Virus (COVID-19), Riffa, Bahrain.
7
Sheikh Mohammed Bin Khalifa Cardiac Centre, Riffa, Bahrain.
8
King Hamad University Hospital, Muharraq, Bahrain.
9
Bahrain Defence Force Hospital, Riffa, Bahrain.
PMID:
36163461
PMCID:
PMC9512917
DOI:
10.1038/s41598-022-20899-w
No abstract available
Publication types
Published Erratum